Swiss Biotech Association, together with EY and six partner organizations, launched the Swiss Biotech Report 2026 during the Swiss Biotech Day 2026 in Basel, highlighting strong growth across Switzerland’s biotech sector in 2025.

The report, themed “Talent and Tenacity,” emphasizes the industry’s ability to attract global talent, foster innovation, and strengthen international partnerships.

According to the report, total revenues generated by Switzerland’s biotech industry reached a record CHF 7.5 billion in 2025, up from CHF 7.2 billion in 2024. Growth was driven by an increasing number of companies reaching the commercial stage and rising demand for specialized CDMO services.

The chemical, pharmaceutical, and life sciences sectors accounted for 53% of Switzerland’s total exports, while immunological products — including therapeutic proteins, vaccines, and cell therapies — contributed a record 20% share.

Total investment in Swiss biotech companies increased to CHF 2.6 billion in 2025. Funding secured by private biotech firms rose 38% year-on-year to a record CHF 1.15 billion, accounting for 45% of total industry funding compared to roughly 30% in previous years.

Employment across Swiss R&D biotech companies also reached a new high, surpassing 21,000 employees as more companies advanced toward commercialization.

Michael Altorfer, CEO of the Swiss Biotech Association, said, “The strong performance of the industry in 2025 is welcome testimony to our commitment to nurturing talent, fostering innovation and promoting international collaboration. Most investment continues to come from abroad and, in USD, is growing at 20 percent year on year — an impressive achievement in the current economic and political climate.”

Frederik Schmachtenberg, EY Partner and Global Life Sciences Lead for Financial Accounting Advisory Services, noted that despite challenging capital markets, Swiss biotech companies maintained strong R&D investment levels and delivered record revenues. He added that the growth in private funding reflects the resilience and confidence of the private investor base.

Among notable private financing rounds in 2025 were Windward Bio with CHF 186 million, GlycoEra with CHF 104 million, Orbis Medicine with CHF 84 million, Nucidium with CHF 79 million, and Rhygaze with CHF 78 million.